Tag Archives: misclassified EpiPen

Sanofi-Aventis Earns $38 Million for Role in Blowing Whistle on Maker of EpiPens

Sanofi-Aventis, a large pharmaceutical company, was awarded $38.7 million for its role in bringing a $465 million False Claims Act case against Mylan. The company settled amid allegations that it knowingly misclassified EpiPen as a generic drug so it could avoid paying back the rebates it owed to Medicaid. The lawsuit was initially filed under […]

By Steve Kardell | Published October 19, 2017 | Posted in Whistleblower Litigation | Tagged FCA claims, Medicaid, misclassified EpiPen | Comments Off on Sanofi-Aventis Earns $38 Million for Role in Blowing Whistle on Maker of EpiPens

Sign Up To Hear More From Steve

Sign Up Now
For Email Marketing you can trust.
Honors
CORPORATE INTERNAL INVESTIGATION & WHISTLEBLOWER LAW LINKS
LOCATION
- Steve Kardell
  
  4514 Cole Ave
  #600
  
  Dallas, Texas 75205
  Phone: 214-306-8045
  Fax: 469-729-9926
READ ARTICLE
FOLLOW US

Testimonials

Reaching out to Steve Kardell was the best decision I made. His ability to provide immediate insight and direction was very powerful, and a huge relief during a very stressful… read more
Steve Kardell was terrific in representing me in some very adversarial discussions with Citigroup and also later represented me in my testimony before the Financial Crisis Inquiry Commission. --Richard Bowen,… read more
As a result of a wrongful termination, I engaged Steve Kardell as legal counsel. Steve took charge of a difficult situation for me and defended my case with my former… read more
I wanted to take the time to write to let you know that I am very pleased with the performance, support, professionalism and determination of Mr. Kardell. Obtaining Mr. Kardell… read more

Tag Archives: misclassified EpiPen

Sanofi-Aventis Earns $38 Million for Role in Blowing Whistle on Maker of EpiPens

Contact Form

Quick Contact Form